<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFACLOR- cefaclor suspension </strong><br>Carlsbad Technology, Inc.<br></p></div>
<h1>Cefaclor for Oral Suspension, USP
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Rx Only
</p>
<p>To reduce the development of drug resistant bacteria and maintain the effectiveness of Cefaclor For Oral Suspension and other antibacterial drugs, Cefaclor For Oral Suspension, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Cefaclor, USP is a semisynthetic cephalosporin antibiotic for oral administration. It is chemically designated as 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate. The chemical formula for cefaclor is C<span class="Sub">15</span>H<span class="Sub">14</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S•H<span class="Sub">2</span>O and the molecular weight is 385.82.
</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f919252-7a87-4386-a64c-5d8213f7e881&amp;name=cef00-0004-01.jpg">
</div>
<p>After mixing, each 5 mL of Cefaclor for Oral Suspension will contain cefaclor monohydrate equivalent to 125 mg (0.34 mmol), 187 mg (0.51 mmol), 250 mg (0.68 mmol), or 375 mg (1.0 mmol) anhydrous cefaclor. The suspensions also contain methylcellulose, sodium lauryl sulfate, sucrose, and xanthan gum, FD&amp;C Red No. 40, strawberry flavor.
</p>
<p>The color of drug powder in the dry powder state is white to off-white. After reconstitution, it turns to a red suspension.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Cefaclor is well absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three fourths to 1 hour later. Following administration of 250 mg, 500 mg, and 1 g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL respectively were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations following the 250 mg, 500 mg and 1 g doses were approximately 600, 900 and 1,900 mcg/mL respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> have not been determined. Hemodialysis shortens the half-life by 25% to 30%.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology
</h2>
<p class="First"><span class="Italics">In vitro</span> tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#s13">INDICATIONS AND USAGE</a></span> section.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.1.1"></a><p></p>
<h3>Aerobes, Gram-positive
</h3>
<p class="First">Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>
</p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus pyogenes</span> (group A β-hemolytic streptococci)
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.1.2"></a><p></p>
<h3>Aerobes, Gram-negative
</h3>
<p class="First"><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Haemophilus influenzae</span>, excluding β-lactamase-negative ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>
</p>
<p><span class="Italics">Klebsiella spp.</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold Underline">but their clinical significance is unknown.</span></p>
<p>Cefaclor exhibits <span class="Italics">in vitro</span> minimal inhibitory concentrations (MICs) of ≤8 mcg/mL against most (≥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of cefaclor in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.1.3"></a><p></p>
<h3>Aerobes, Gram-negative
</h3>
<p class="First"><span class="Italics">Citrobacter diversus</span></p>
<p><span class="Italics">Moraxella (Branhamella) catarrhalis</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-3.1.4"></a><p></p>
<h3>Anaerobes, Gram-positive
</h3>
<p class="First"><span class="Italics">Bacteroides spp.</span> (excluding <span class="Italics">Bacteroides fragilis</span>)
</p>
<p>Peptococcus
</p>
<p><span class="Italics">Peptostreptococcus</span></p>
<p><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Italics">Note: Pseudomonas</span> spp., <span class="Italics">Acinetobacter calcoaceticus</span> and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci (<span class="Italics">Enterococcus faecalis</span>, group D streptococci), <span class="Italics">Enterobacter</span> spp., indole-positive <span class="Italics">Proteus</span>, <span class="Italics">Morganella morganii</span> (formerly <span class="Italics">Proteus morganii</span>), <span class="Italics">Providencia rettgeri</span> (formerly <span class="Italics">Proteus rettgeri</span>), and <span class="Italics">Serratia</span> spp. are resistant to cefaclor. When tested by <span class="Italics">in vitro</span> methods, staphylococci exhibit cross-resistance between cefaclor and methicillin-type antibiotics.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Testing
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-3.2.1"></a><p></p>
<p class="First"><span class="Bold">Dilution Techniques --</span> Quantitative methods that are used to determine <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC) provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure that has been recommended for use with cefaclor powder uses a standardized dilution method <span class="Sup">1</span> (broth, agar, or microdilution). The MIC values obtained should be interpreted according to the following criteria:
</p>
<table width="100%">
<col align="left" width="45.900%">
<col align="left" width="54.100%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">MIC (mcg /mL)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Interpretation *
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">≤8
</td>
<td class="Botrule Rrule" align="center" valign="middle">Susceptible (S)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">16
</td>
<td class="Botrule Rrule" align="center" valign="middle">Intermediate (I)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">≥32
</td>
<td class="Botrule Rrule" align="center" valign="middle">Resistant (R)
</td>
</tr>
</tbody>
</table>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="justify" valign="middle">* When testing <span class="Italics">H. influenzae</span> spp. these interpretive standards are applicable only to broth microdilution method using Haemophilus Test Medium (HTM)<span class="Sup">1</span>
</td></tr></tbody>
</table>
<p><span class="Bold">Note:</span> β-lactamase-negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro</span> susceptibility to this agent.
</p>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.
</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms. Standard cefaclor powder should provide the following MIC values:
</p>
<table width="100%">
<col align="left" width="78.050%">
<col align="left" width="21.950%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First Footnote">*Broth microdilution test performed using Haemophilus Test Medium (HTM) <span class="Sup">1</span></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Microorganism
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">MIC (mcg /mL)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">E. coli</span>    ATCC 25922
</td>
<td class="Botrule Rrule" align="center" valign="middle">1-4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">E. faecalis</span>    ATCC 29212
</td>
<td class="Botrule Rrule" align="center" valign="middle">&gt;32
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">S. aureus</span>    ATCC 29213
</td>
<td class="Botrule Rrule" align="center" valign="middle">1-4
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle">When testing <span class="Italics">H. influenzae</span> *
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Microorganism
</td>
<td class="Botrule Rrule" align="center" valign="middle">MIC (mcg /mL)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">H. influenzae</span>    ATCC 49766
</td>
<td class="Botrule Rrule" align="center" valign="middle">1-4
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-3.2.2"></a><p></p>
<p class="First"><span class="Bold">Diffusion Techniques</span> -- Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> that has been recommended for use with disks to test the susceptibility of microorganisms to cefaclor uses the 30-mcg cefaclor disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefaclor. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-mcg cefaclor disk should be interpreted according to the following criteria:
</p>
<p>When Testing Organisms Other Than <span class="Italics">Haemophilus</span> spp. and Streptococci
</p>
<table width="100%">
<col align="left" width="57.250%">
<col align="left" width="42.750%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Zone Diameter (mm)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Interpretation
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">≥18
</td>
<td class="Botrule Rrule" align="center" valign="middle">Susceptible (S)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">15-17
</td>
<td class="Botrule Rrule" align="center" valign="middle">Intermediate (I)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">≤14
</td>
<td class="Botrule Rrule" align="center" valign="middle">Resistant (R)
</td>
</tr>
</tbody>
</table>
<table width="100%">
<col align="left" width="57.250%">
<col align="left" width="42.750%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First Footnote">*Disk susceptibility test performed using Haemophilus Test Medium (HTM) <span class="Sup">2</span></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle">When testing <span class="Italics">H. influenzae</span> *
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Zone Diameter (mm)
</td>
<td class="Botrule Rrule" align="center" valign="middle">Interpretation
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">≥20
</td>
<td class="Botrule Rrule" align="center" valign="middle">Susceptible (S)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">17-19
</td>
<td class="Botrule Rrule" align="center" valign="middle">Intermediate (I)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">≤16
</td>
<td class="Botrule Rrule" align="center" valign="middle">Resistant (R)
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Note:</span> β-lactamase-negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro</span> susceptibility to this agent.
</p>
<p>Interpretation should be as stated above for results using diffusion techniques.
</p>
<p>As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The 30-mcg cefaclor disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:
</p>
<table width="100%">
<col align="left" width="57.150%">
<col align="left" width="42.850%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First Footnote">*Disk susceptibility test performed using Haemophilus Test Medium (HTM)<span class="Sup">2</span></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Microorganism
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Zone Diameter (mm)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">E. coli</span>             ATCC 25922
</td>
<td class="Botrule Rrule" align="center" valign="middle">23-27
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">S. aureus</span>        ATCC 25923
</td>
<td class="Botrule Rrule" align="center" valign="middle">27-31
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle">When testing H. influenzae *
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Microorganism
</td>
<td class="Botrule Rrule" align="center" valign="middle">Zone Diameter (mm)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Italics">H. influenzae</span>   ATCC 49766
</td>
<td class="Botrule Rrule" align="center" valign="middle">25-31
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s13"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Cefaclor is indicated in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms:
</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span></span> caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae</span>, staphylococci, and <span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">Note:</span> β-lactamase-negative, ampicillin-resistant (BLNAR) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae</span> should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro</span> susceptibility of some BLNAR <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.
</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span>,</span> including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae</span>, and <span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">Note:</span> β-lactamase-negative, ampicillin-resistant (BLNAR) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae</span> should be considered resistant to cefaclor despite apparent <span class="Italics">in vitro</span> susceptibility of some BLNAR <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.
</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></span>, caused by <span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">Note:</span> Penicillin is the usual drug of choice in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Cefaclor in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available at present.
</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span>,</span> including <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span> and <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, caused by <span class="Italics">Escherichia coli</span>, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Klebsiella</span> spp., and coagulase-negative staphylococci
</p>
<p><span class="Underline">Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> caused by <span class="Italics">Staphylococcus aureus</span> and <span class="Italics">Streptococcus pyogenes</span></p>
<p>Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.
</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor For Oral Suspension and other antibacterial drugs, Cefaclor For Oral Suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s14"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Cefaclor is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s15"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First"><span class="Bold">BEFORE THERAPY WITH CEFACLOR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFACLOR, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>.</span></p>
<p><span class="Bold">IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFACLOR OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span></p>
<p>Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, particularly to drugs.
</p>
<p><span class="Bold Italics">Clostridium difficile
</span><span class="Bold">associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Cefaclor For Oral Suspension, USP, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of
</span><span class="Bold Italics">C. difficile.</span></p>
<p><span class="Bold Italics">C. difficile
</span><span class="Bold">produces toxins A and B which contribute to the development of CDAD, Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of
</span><span class="Bold Italics">C. difficile
</span><span class="Bold">cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</span></p>
<p><span class="Bold">If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
</span><span class="Bold Italics">C.  difficile
</span><span class="Bold">may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of
</span><span class="Bold Italics">C. difficile</span><span class="Bold">, and surgical evaluation should be instituted as clinically indicated.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s16"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s17"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">Prescribing cefaclor in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increase the risk of the development of drug-resistant bacteria.
</p>
<p>Prolonged use of cefaclor may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.
</p>
<p>Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. It should be recognized that a positive Coombs' test may be due to the drug, e.g., in hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition.
</p>
<p>Cefaclor should be administered with caution in the presence of markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Since the half-life of cefaclor in <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> is 2.3 to 2.8 hours, dosage adjustments for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are usually not required. Clinical experience with cefaclor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.
</p>
<p>As with other β-lactam antibiotics, the renal excretion of cefaclor is inhibited by probenecid.
</p>
<p>Antibiotics, including cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s18"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Cefaclor for Oral Suspension should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Cefaclor for Oral Suspension is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping dose on not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefaclor for Oral Suspension or other antibacterial drugs in the future.
</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s19"></a><a name="section-7.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions
</h2>
<p class="First">Patients receiving cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest<span class="Sup">®</span> tablets.
</p>
<p>There have been reports of increased anticoagulant effect when cefaclor and oral anticoagulants were administered concomitantly.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s20"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Studies have not been performed to determine potential for carcinogenicity, mutagenicity, or impairment of fertility.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s21"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy -- Teratogenic Effects -- Pregnancy Category B
</h2>
<p class="First">Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no harm to the fetus due to cefaclor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s22"></a><a name="section-7.6"></a><p></p>
<h2>Labor and Delivery
</h2>
<p class="First">The effect of cefaclor on labor and delivery is unknown.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s23"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">Small amounts of cefaclor have been detected in mother's milk following administration of single 500-mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/mL at 2, 3, 4, and 5 hours respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefaclor is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s24"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s25"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">Of the 3703 patients in clinical studies of cefaclor, 594 (16.0%) were 65 and older.  No overall differences in safety of effectiveness were observed between these subjects and younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
</p>
<p>This drug is known to be substantially excreted by the kidney (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>), and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#s31">DOSAGE AND ADMINISTRATION</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s26"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Adverse effects considered to be related to therapy with cefaclor are listed below:
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span> reactions have been reported in about 1.5% of patients and include <span class="product-label-link" type="condition" conceptid="4083309" conceptname="Morbilliform eruption">morbilliform eruptions</span> (1 in 100). <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and positive Coombs' tests each occur in less than 1 in 200 patients.
</p>
<p>Cases of <span class="Bold">serum-sickness-like</span> reactions have been reported with the use of cefaclor. These are characterized by findings of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, and other skin manifestations accompanied by <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>/<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and differ from classic <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> in that there is infrequently associated <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> and <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, no circulating immune complexes, and no evidence to date of sequelae of the reaction. Occasionally, solitary symptoms may occur, but do not represent a <span class="Bold">serum-sickness-like</span> reaction. While further investigation is ongoing, <span class="Bold">serum-sickness-like</span> reactions appear to be due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in pediatric patients than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) in overall clinical trials (with an incidence in pediatric patients in clinical trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in pediatric patients. Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported.
</p>
<p>More severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported rarely. Anaphylactoid events may be manifested by solitary symptoms, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (including face and limbs), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> may be more common in patients with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.
</p>
<p>Rarely, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> symptoms may persist for several months.
</p>
<p><span class="Italics">Gastrointestinal</span> symptoms occur in about 2.5% of patients and include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 in 70).
</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment (see <span class="Bold"><a href="#s15">WARNINGS</a></span> ). <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported rarely. As with some penicillins and some other cephalosporins, transient <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> have been reported rarely.
</p>
<p><span class="Italics">Other</span> effects considered related to therapy included <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (1 in 50 patients), <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> or <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (about 1 in 50 patients), and, rarely, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or reversible interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.
</p>
<p><span class="Italics">Causal Relationship Uncertain</span> --
</p>
<p><span class="Italics">CNS</span> -- Rarely, reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> have been reported.
</p>
<p>Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.
</p>
<p><span class="Italics">Hepatic</span> -- Slight elevations of AST, ALT, or alkaline phosphatase values (1 in 40).
</p>
<p><span class="Italics">Hematopoietic</span> -- As has also been reported with other β-lactam antibiotics, transient <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> of possible clinical significance.
</p>
<p>There have been rare reports of increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time with or without clinical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients receiving cefaclor and Coumadin<span class="Sup">®</span> concomitantly.
</p>
<p><span class="Italics">Renal</span> -- Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-8.1"></a><p></p>
<h2>Cephalosporin-class Adverse Reactions
</h2>
<p class="First">In addition to the adverse reactions listed above that have been observed in patients treated with cefaclor, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, false positive test for urinary glucose, elevated bilirubin, elevated LDH, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.
</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced. If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (see <span class="Bold"><a href="#s31">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#s28">OVERDOSAGE</a></span> sections).
</p>
<p>


To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s28"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Italics">Signs and Symptoms</span> -- The toxic symptoms following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of cefaclor may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. The severity of the <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span> and the <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> are dose related. If other symptoms are present, it is probable that they are secondary to an underlying disease state, an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, or the effects of other <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Italics">Treatment</span> -- To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians' Desk Reference (PDR).</span> In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.
</p>
<p>Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal decontamination will not be necessary.
</p>
<p>Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.
</p>
<p>Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of cefaclor.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s31"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Cefaclor is administered orally.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Italics">Adults</span> -- The usual adult dosage is 250 mg every 8 hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) or those caused by less susceptible organisms, doses may be doubled.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-10.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients</span> -- The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours. In more serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by less susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage of 1 g/day.
</p>
<table width="100%">
<col align="left" width="21.967%">
<col align="left" width="38.933%">
<col align="left" width="39.100%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle">Cefaclor Suspension
</td>
</tr>
<tr><td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">20 mg/kg/day</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Underline">Weight</span></td>
<td class="Botrule Rrule" align="right" valign="middle"><span class="Underline">125 mg/5 mL</span></td>
<td class="Botrule Rrule" align="right" valign="middle"><span class="Underline">250 mg/5 mL</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">9 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle">1/2 tsp t.i.d.
</td>
<td class="Botrule Rrule" align="right" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">18 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle">1 tsp t.i.d.
</td>
<td class="Botrule Rrule" align="right" valign="middle">1/2 tsp t.i.d.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">40 mg/kg/day</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">9 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle">1 tsp t.i.d.
</td>
<td class="Botrule Rrule" align="right" valign="middle">1/2 tsp t.i.d.
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">18 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle"></td>
<td class="Botrule Rrule" align="right" valign="middle">1 tsp t.i.d.
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-10.3"></a><p></p>
<p class="First"><span class="Italics">B.I.D. Treatment Option</span> —For the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, the total daily dosage may be divided and administered every 12 hours.
</p>
<table width="100%">
<col align="left" width="21.967%">
<col align="left" width="38.933%">
<col align="left" width="39.100%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle">Cefaclor Suspension
</td>
</tr>
<tr><td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">20 mg/kg/day <br>(<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Underline">Weight</span></td>
<td class="Botrule Rrule" align="right" valign="middle"><span class="Underline">187 mg/5 mL</span></td>
<td class="Botrule Rrule" align="right" valign="middle"><span class="Underline">375 mg/5 mL</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">9 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle">1/2 tsp b.i.d.
</td>
<td class="Botrule Rrule" align="right" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">18 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle">1 tsp b.i.d.
</td>
<td class="Botrule Rrule" align="right" valign="middle">1/2 tsp b.i.d.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">40 mg/kg/day <br>(<span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">9 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle">1 tsp b.i.d.
</td>
<td class="Botrule Rrule" align="right" valign="middle">1/2 tsp b.i.d.
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">18 kg
</td>
<td class="Botrule Rrule" align="right" valign="middle"></td>
<td class="Botrule Rrule" align="right" valign="middle">1 tsp b.i.d.
</td>
</tr>
</tbody>
</table>
<p>Cefaclor may be administered in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Under such a condition, the dosage usually is unchanged (see <span class="Bold"><a href="#s16">PRECAUTIONS</a></span>).
</p>
<p>In the treatment of β-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic dosage of cefaclor should be administered for at least 10 days.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-10.4"></a><p></p>
<h2>Directions for Mixing:
</h2>
<p class="First">Add appropriate water volume as indicated in the following table in two portions to dry mixture in the bottle. Shake well after each addition.
</p>
<p>Each 5 mL (Approx. one teaspoonful) will then contain Cefaclor USP monohydrate equivalent to 125 mg, 187 mg, 250 mg or 375 mg anhydrous cefaclor respectively as shown in the following table.
</p>
<p>Oversize bottle provides extra space for <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>.
</p>
<table width="100%">
<col align="left" width="35.267%">
<col align="left" width="31.000%">
<col align="left" width="33.733%">
<thead><tr class="First Last"><th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Cefaclor For Oral Suspension, USP</span></th></tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<span class="Bold">Strength</span><br>Package Size (when mixed)
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">Water Volume to Add</span></td>
<td class="Botrule Rrule" align="center" valign="middle">Anhydrous Cefaclor/5 mL<br>(Approx. one teaspoonful)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">
<span class="Bold">125 mg/5 mL</span><br>
</td>
<td class="Rrule" align="left" valign="middle"></td>
<td class="Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">75 mL
</td>
<td class="Rrule" align="center" valign="middle"><span class="Bold Italics">53 mL</span></td>
<td class="Rrule" align="center" valign="middle">125 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">150 mL
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">106 mL</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle"><span class="Bold">187 mg/5 mL</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">50 mL
</td>
<td class="Rrule" align="center" valign="middle"><span class="Bold Italics">35 mL</span></td>
<td class="Rrule" align="center" valign="middle">187 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">100 mL
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">70 mL</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle"><span class="Bold">250 mg/5 mL</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">75 mL
</td>
<td class="Rrule" align="center" valign="middle"><span class="Bold Italics">53 mL</span></td>
<td class="Rrule" align="center" valign="middle">250 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">150 mL
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">106 mL</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle"><span class="Bold">375 mg/5 mL</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">50 mL
</td>
<td class="Rrule" align="center" valign="middle"><span class="Bold Italics">34 mL</span></td>
<td class="Rrule" align="center" valign="middle">375 mg
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">100 mL
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold Italics">68 mL</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s36"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Cefaclor Oral Suspension, USP are supplied in bottles with child-resistant caps as:
</p>
<p>125 mg/5 mL strawberry flavor:
</p>
<dl>
<dt> 
</dt>
<dd>NDC 61442-173-02 (75-mL size)
</dd>
<dt> 
</dt>
<dd>NDC 61442-173-01 (150-mL size)
</dd>
</dl>
<p>187 mg/5 mL strawberry flavor
</p>
<dl>
<dt> 
</dt>
<dd>NDC 61442-174-02 (50-mL size)
</dd>
<dt> 
</dt>
<dd>NDC 61442-174-01 (100-mL size)
</dd>
</dl>
<p>250 mg/5 mL strawberry flavor
</p>
<dl>
<dt> 
</dt>
<dd>NDC 61442-175-02 (75-mL size)
</dd>
<dt> 
</dt>
<dd>NDC 61442-175-01 (150-mL size)
</dd>
</dl>
<p>375 mg/5 mL strawberry flavor
</p>
<dl>
<dt> 
</dt>
<dd>NDC 61442-176-02 (50-mL size)
</dd>
<dt> 
</dt>
<dd>NDC 61442-176-01 (100-mL size)
</dd>
</dl>
<p>After mixing, store in a refrigerator. Shake well before using. Keep tightly closed. The mixture may be kept for 14 days without significant loss of potency. Discard unused portion after 14 days.
</p>
<p>Store dry powder at 20∘to 25℃ (68∘to 77℉). [See USP Controlled Room Temperature].
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s37"></a><a name="section-12"></a><p></p>
<h1>REFERENCES
</h1>
<ol class="Arabic">
<li> National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically--Fourth Edition. Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS, Wayne, PA, January, 1997.
</li>
<li> National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests — “Sixth Edition, Approved? Standard NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS, Wayne, PA, January, 1997.
</li>
</ol>
<p class="First"><span class="Bold">Manufactured by:<br></span>Yung Shin Pharmaceutical Ind. Co., Ltd.<br>Tachia, Taichung 43769<br>TAIWAN
</p>
<p><span class="Bold">Distributed by:<br></span>Carlsbad Technology, Inc.,<br>5923 Balfour Court, <br>Carlsbad, CA 92008, U.S.A
</p>
<p>Revised: 03/12
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s38"></a><a name="section-13"></a><p></p>
<h1>Principal Display Panel - 125mg Bottle Label
</h1>
<p class="First">NDC 61442-173-02<br><span class="Bold Italics">CEFACLOR</span><br>For Oral Suspension, USP<br>125 mg per 5 mL<br><span class="Bold">75 mL (when mixed)</span><br>SHAKE WELL BEFORE USE<br><span class="Bold Italics">Rx
</span><span class="Bold">Only</span><br><span class="Bold Italics">Carlsbad Technology, Inc.</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel - 125mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f919252-7a87-4386-a64c-5d8213f7e881&amp;name=cef00-0004-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s39"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel - 250mg Bottle Label
</h1>
<p class="First">NDC 61442-175-02<br><span class="Bold Italics">CEFACLOR</span><br>For Oral Suspension, USP<br>250 mg per 5 mL<br>75 mL (when mixed)<br>SHAKE WELL BEFORE USE<br><span class="Bold Italics">Rx</span> Only<br><span class="Bold Italics">Carlsbad Technology, Inc.</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel - 250mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f919252-7a87-4386-a64c-5d8213f7e881&amp;name=cef00-0004-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s40"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel - 375mg Bottle Label
</h1>
<p class="First">NDC 61442-176-02<br><span class="Bold Italics">CEFACLOR</span><br>For Oral Suspension, USP<br>375 mg per 5 mL<br><span class="Bold">50 mL (when mixed)</span><br>SHAKE WELL BEFORE USE<br><span class="Bold Italics">Rx</span> Only<br><span class="Bold Italics">Carlsbad Technology, Inc.</span></p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel - 375mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f919252-7a87-4386-a64c-5d8213f7e881&amp;name=cef00-0004-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s41"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel - 187mg Bottle Label
</h1>
<p class="First">NDC 61442-174-02<br><span class="Bold Italics">CEFACLOR
</span><br>For Oral Suspension, USP<br>187 mg per 5 mL<br><span class="Bold">50 mL (when mixed)</span><br>SHAKE WELL BEFORE USE<br><span class="Bold Italics">Rx
</span><span class="Bold">Only</span><br><span class="Bold Italics">Carlsbad Technology, Inc.</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Principal Display Panel - 187mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f919252-7a87-4386-a64c-5d8213f7e881&amp;name=cef00-0004-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFACLOR 		
					</strong><br><span class="contentTableReg">cefaclor suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61442-173</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefaclor</strong> (Cefaclor Anhydrous) </td>
<td class="formItem">Cefaclor Anhydrous</td>
<td class="formItem">125 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (25 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY (STRAWBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61442-173-02</td>
<td class="formItem">75 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61442-173-01</td>
<td class="formItem">150  mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065412</td>
<td class="formItem">03/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFACLOR 		
					</strong><br><span class="contentTableReg">cefaclor suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61442-174</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefaclor</strong> (Cefaclor Anhydrous) </td>
<td class="formItem">Cefaclor Anhydrous</td>
<td class="formItem">187 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (25 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY (STRAWBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61442-174-02</td>
<td class="formItem">50 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61442-174-01</td>
<td class="formItem">100 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065412</td>
<td class="formItem">03/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFACLOR 		
					</strong><br><span class="contentTableReg">cefaclor suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61442-175</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefaclor</strong> (Cefaclor Anhydrous) </td>
<td class="formItem">Cefaclor Anhydrous</td>
<td class="formItem">250 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (25 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY (STRAWBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61442-175-02</td>
<td class="formItem">75 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61442-175-01</td>
<td class="formItem">150 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065412</td>
<td class="formItem">03/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFACLOR 		
					</strong><br><span class="contentTableReg">cefaclor suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61442-176</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Cefaclor</strong> (Cefaclor Anhydrous) </td>
<td class="formItem">Cefaclor Anhydrous</td>
<td class="formItem">375 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (25 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY (STRAWBERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61442-176-02</td>
<td class="formItem">50 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:61442-176-01</td>
<td class="formItem">100 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065412</td>
<td class="formItem">03/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carlsbad Technology, Inc.
							(781047246)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Yung Shin Pharmaceutical Industrual Co., Ltd. (658843289)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Yung Shin Pharmaceutical Industrial Co., Ltd.</td>
<td class="formItem"></td>
<td class="formItem">658843289</td>
<td class="formItem">MANUFACTURE(61442-173, 61442-174, 61442-175, 61442-176), PACK(61442-173, 61442-174, 61442-175, 61442-176), LABEL(61442-173, 61442-174, 61442-175, 61442-176)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>58b43cb7-d360-4ef5-bbef-a4b81af7c1ff</div>
<div>Set id: 9f919252-7a87-4386-a64c-5d8213f7e881</div>
<div>Version: 2</div>
<div>Effective Time: 20120327</div>
</div>
</div> <div class="DistributorName">Carlsbad Technology, Inc.</div></p>
</body></html>
